Malignant News and Research

RSS

Cook Medical begins clinical study to evaluate removability of Evolution Esophageal Fully Covered Stent

Cook Medical has initiated a clinical study in the U.S. to evaluate the removability of a new Evolution Esophageal Fully Covered Stent. This is the first multicenter U.S. study to evaluate the possibility of removing a self-expanding metal stent after malignant and benign strictures have been treated. The stent design used in the study has been modified to accommodate retrieval.

12 Dec 2013

New reports demonstrate the effectiveness of modified T cells in treating blood-borne cancers

At the 2013 American Society of Hematology meeting in Dec. 2013, James Kochenderfer, M.D., investigator in the Experimental Transplantation and Immunology Branch, NCI, presented findings from two clinical trials evaluating the use of genetically modified immune system T cells as cancer therapy.

12 Dec 2013

Report: Screen all endometrial cancer patients for Lynch syndrome

A recent article by Norris Cotton Cancer Center researchers published in the January 2014 issue of the journal Clinical Chemistry reviews the scientific evidence that warrants screening all endometrial cancers for Lynch syndrome. Next to colorectal cancer, endometrial cancer is the most common form of cancer in women with Lynch syndrome.

12 Dec 2013

Johns Hopkins researchers use lung cancer drug to shrink chordoma in mice

Johns Hopkins researchers say that a drug approved to treat lung cancer substantially shrank tumors in mice that were caused by a rare form of bone cancer called chordoma.

12 Dec 2013

Study shows children with ALL can safely receive intravenous infusions of chemotherapy

Children with acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer, can safely receive intravenous infusions of a reformulated mainstay of chemotherapy that has been delivered via painful intramuscular injection for more than 40 years, research suggests.

11 Dec 2013

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, announced that positive preclinical data of selective HDAC6 inhibitor, ricolinostat (ACY-1215), in models of lymphoma were presented today in an oral presentation by Dr. Jennifer Amengual, Assistant Professor of Medicine & Experimental Therapeutics, Columbia University Medical Center.

10 Dec 2013

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops targeted, antibody-based anticancer therapeutics, today announced the first clinical findings with SAR650984 reported in an oral presentation at the ASH annual meeting. The data are from an ongoing Phase I trial assessing this CD38-targeting therapeutic antibody in patients with CD38-positive MM or other hematologic malignancy.

10 Dec 2013

Signs of inflammation in man’s prostate biopsy may indicate reduced risk

Signs of inflammation in a man’s prostate biopsy may indicate he has a reduced risk of subsequently being diagnosed with prostate cancer in a future biopsy. That’s the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

9 Dec 2013

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

Novartis is highlighting new research from members of the faculty at the University of Pennsylvania’s Perelman School of Medicine on the investigational chimeric antigen receptor therapy, CTL019. Several studies being presented at the American Society of Hematology annual meeting add to the scientific understanding of CTL019 in the treatment of acute lymphoblastic leukemia and chronic lymphocytic leukemia and build on earlier research findings.

9 Dec 2013

Study reveals that brain cancer cells resist therapy by dialing down gene mutation targeted by drugs

A team of scientists, led by principal investigator Paul S. Mischel, MD, a member of the Ludwig Institute for Cancer Research and professor in the Department of Pathology at the University of California, San Diego School of Medicine, has found that brain cancer cells resist therapy by dialing down the gene mutation targeted by drugs, then re-amplify that growth-promoting mutation after therapy has stopped.

6 Dec 2013

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia, following acceptance of its Investigational New Drug application by the U.S. Food and Drug Administration.

5 Dec 2013

BIDMC study shows carbon monoxide may have a role to play in treating cancer

In recent years, research has suggested that carbon monoxide, the highly toxic gas emitted from auto exhausts and faulty heating systems, can be used to treat certain inflammatory medical conditions. Now a study led by a research team at Beth Israel Deaconess Medical Center (BIDMC) shows for the first time that carbon monoxide may also have a role to play in treating cancer.

4 Dec 2013

Better understanding of cancer evolution could help in early detection of cancers

A new appreciation of how cancer cells evolve could help scientists design better screening methods to catch cancer before it advances.

4 Dec 2013

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

The Fred Hutchinson Cancer Research Center (Fred Hutch) and Memorial Sloan-Kettering Cancer Center (MSKCC), along with pediatric partner Seattle Children's Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer.

4 Dec 2013

Mount Sinai cardiologists contribute to the creation of new cardiomyopathy classification system

Leading cardiologists at The Mount Sinai Hospital have contributed to the development of a new classification system called MOGE(S) for cardiomyopathies, the diseases of the heart muscle which can lead to heart enlargement and heart failure.

4 Dec 2013

People who suffer with chronic pain face daily struggle with sense of self

People who suffer with chronic musculoskeletal pain face a daily struggle with their sense of self and find it difficult to prove the legitimacy of their condition.

3 Dec 2013

Researchers use hyperthermia to treat patients with malignant glioma

Malignant glioma is very sensitive to heat. Prof. Yunlong Ge and team from the Second Affiliated Hospital of Harbin Medical University, China used a brain tumor hyperthermia apparatus to treat malignant glioma patients, and achieved good therapeutic efficacy.

3 Dec 2013

Malignant News and Research

Cook Medical begins clinical study to evaluate removability of Evolution Esophageal Fully Covered Stent

New reports demonstrate the effectiveness of modified T cells in treating blood-borne cancers

Report: Screen all endometrial cancer patients for Lynch syndrome

Johns Hopkins researchers use lung cancer drug to shrink chordoma in mice

Study shows children with ALL can safely receive intravenous infusions of chemotherapy

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

Signs of inflammation in man’s prostate biopsy may indicate reduced risk

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

Study reveals that brain cancer cells resist therapy by dialing down gene mutation targeted by drugs

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

BIDMC study shows carbon monoxide may have a role to play in treating cancer

Better understanding of cancer evolution could help in early detection of cancers

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

Mount Sinai cardiologists contribute to the creation of new cardiomyopathy classification system

People who suffer with chronic pain face daily struggle with sense of self

Researchers use hyperthermia to treat patients with malignant glioma

New biomarkers to improve diagnostics of prostate cancer

NHPA report compares performance of Queensland hospitals on cancer surgeries

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News